Literature DB >> 22194120

The safety and diagnostic value of frame-based and CT-guided stereotactic brain biopsy technique.

Mehmet Ersahin1, Numan Karaaslan, Mehmet Sabri Gurbuz, Tayfun Hakan, Mehmet Zafer Berkman, Osman Ekinci, Nazım Denizli, Fugen Vardar Aker.   

Abstract

AIM: Histopathological diagnosis is always necessary to make an effective treatment plan for intracranial mass lesions. This study aimed to evaluate the diagnostic efficacy, and associated mortality and morbidity of CT-guided stereotactic biopsy procedures in a large number of patients with intracranial lesions.
MATERIAL AND METHODS: A total of 290 cases undergoing CT-guided stereotactic biopsy for intracranial lesions were included in this retrospective study. Clinical, radiological and histological data in patient records were examined.
RESULTS: The mean age of the patients was 46.6 years (range: 2-82 y). Pediatric patients comprised 6.3% (n=13) of the total population. Examination of paraffin embedded histological preparations revealed a tumoral mass in 240 (82.8%), a non-tumoral mass in 37 (12.8%), and non-definable lesions in 13 (4.5%). Therefore, the diagnostic value in this series was 95.5%. Postoperative mortality rate was 0.8% (n=2). When histopathological diagnoses made after biopsy and surgical resection were compared in 42 patients with available data, a complete or partial agreement was present in 90.5%.
CONCLUSION: Our findings support that frame based-stereotactic biopsy is a safe and valuable technique that allows the neurosurgeon to obtain tissue samples for histopathological diagnosis of intracranial mass lesions in almost any region.

Entities:  

Mesh:

Year:  2011        PMID: 22194120     DOI: 10.5137/1019-5149.JTN .4656-11.1

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  8 in total

1.  Real-time MR-guided brain biopsy using 1.0-T open MRI scanner.

Authors:  Xiangmeng He; Ming Liu; Chao Liu; Jing Fang; Yujun Xu; Ligang Wang; Jianfeng Xiang; Roberto Blanco Sequeiros; Chengli Li
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

2.  Primary intracranial extraskeletal myxoid chondrosarcoma: A case report and review of literature.

Authors:  Zi-You Zhu; Yu-Bo Wang; Han-Yi Li; Xin-Min Wu
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

Review 3.  Intraoperative MRI for Brain Tumors.

Authors:  Cara Marie Rogers; Pamela S Jones; Jeffrey S Weinberg
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 4.  The role of biopsy in the management of patients with presumed diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Brian T Ragel; Timothy C Ryken; Steven N Kalkanis; Mateo Ziu; Daniel Cahill; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

5.  Synergistic actions of olomoucine and bone morphogenetic protein-4 in axonal repair after acute spinal cord contusion.

Authors:  Liang Chen; Jianjun Li; Liang Wu; Mingliang Yang; Feng Gao; Li Yuan
Journal:  Neural Regen Res       Date:  2014-10-15       Impact factor: 5.135

6.  Role of high-field intraoperative magnetic resonance imaging on a multi-image fusion-guided stereotactic biopsy of the basal ganglia: A case report.

Authors:  Xiang Sun; Zhijuan Chen; Shuyuan Yang; Jianning Zhang; Shuyuan Yue; Zengguang Wang; Weidong Yang
Journal:  Oncol Lett       Date:  2014-11-07       Impact factor: 2.967

7.  Diagnostic yield of stereotactic needle-biopsies of sub-cubic centimeter intracranial lesions.

Authors:  J Dawn Waters; David D Gonda; Hasini Reddy; Ekkehard M Kasper; Peter C Warnke; Clark C Chen
Journal:  Surg Neurol Int       Date:  2013-04-17

8.  Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures.

Authors:  Jan-Oliver Neumann; Benito Campos; Bilal Younes; Martin Jakobs; Christine Jungk; Christopher Beynon; Andreas von Deimling; Andreas Unterberg; Karl Kiening
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.